Navigation Links
Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Date:4/22/2009

LAIYANG, China, April 22 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it began marketing and selling three Traditional Chinese Medicines ("TCMs"). These TCMs are Yi Mu Cao Gao (a motherwort herb electuary sticky syrup), Gan Mao Zhi Ke Ke Li (an antipyretic and antitussive granule), and Kang Gu Sui Yan Pian (an osteomyelitis treatment tablet).

The Company recently purchased 22 TCMs with SFDA drug regulatory agency approvals for manufacturing and distribution from Hongrui Pharmaceuticals. The three TCMs which Genesis is now beginning to market and distribute are the first three products Genesis acquired from Hongrui to be relabeled and sold under Genesis' brand name "Jiangbo." All three Hongrui products are being sold through the 28 independent distributors used by Genesis.

Yi Mu Cao Gao is used to treat dysmenorrhoea, oligminorrhea and postpartum abdominal pain. It is included in China's provincial and national medical insurance catalogues, which means consumers are reimbursed for the cost of purchasing this product.

Gan Mao Zhi Ke Ke Li antipyretic and antitussive granules help relieve cold and flu symptoms such as fever, headache, rhinocleisis, cough, throat pain and phlegm. It is used in a large number of China's hospitals and clinics and is popular with consumers. Proposed healthcare reforms in China are expected to result in more hospitals and clinics carrying Gan Mao Zhi Ke Ke Li, making it even more widely available to consumers.

Kang Gu Sui Yan Pian osteomyelitis treatment tablets are used to treat bone and bone marrow inflammations. Osteomyelitis patients may develop resistance if treated by chemical drugs, such as antibiotics, for a long period of time. Chronic patients are also likely to need surgery. A 100% herb-based Traditional Chinese Medicine, Genesis' osteomyelitis tablets offer an alternative treatment which is mild and was clinically tested to be effective in treating long term osteomyelitis problems. Genesis is the exclusive manufacturer of this product in China.

Sales of these three products are expected to be $1.5 million in the Company's fiscal year 2009, which ends on June 30, 2009, and an estimated $7.3 million in fiscal year 2010.

"We are pleased to launch these three products so quickly after taking control over Hongrui," said Mr. Wubo Cao, Chief Executive Officer of Genesis. "Generally speaking, TCMs are popular in rural China because they are less expensive than western medicines. We plan to increase our marketing and sales efforts for all of our TCM products in rural areas in conjunction with government plans to expand healthcare services there."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in time release tablet, capsule, granule, syrup and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Genesis Pharmaceuticals Enterprises, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.genesispharmaceuticals.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. EURYI project to understand how the brain wires during embryogenesis
3. DNA damage response confers a barrier for viral tumorigenesis
4. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
5. The genetics of MLL leukemogenesis
6. Genesis Technology Group Retains CCG Elite
7. Researchers chart the genetic mechanisms behind the genesis of fat cells
8. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
9. ThermoGenesis Corp. Reports First Quarter 2008 Results
10. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
11. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has ... Diego, CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. ... not invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. ... Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , ... quality of their product, through activities that focus on better farming, better lives and ...
(Date:2/10/2016)... Fort Walton Beach, Florida (PRWEB) , ... February ... ... that the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at ... new platform, MetLoop has “put the power of the world's most advanced weather ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... England och PITTSBURGH ... Erbjudandet lämnas inte, och detta pressmeddelande ... indirekt, i eller till, och inga anmälningssedlar ... av aktieägare i, något land där Erbjudandet, ... accept av Erbjudandet skulle strida mot tillämpliga ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the market ... treatment of Benign Prostatic Hyperplasia (BPH), announces new private ... Keswani , a medical device industry veteran of more ... Limited Liability Company.  Plymouth, Minn. ... lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue ...
Breaking Medicine Technology: